Small Molecules Still Out in Front
Posted by admin in News, tags: biologics, clinical trials, small moleculeAlthough many companies do not publicise trials, the available evidence shows that biologics are still lagging behind traditional small molecules in the drug development stakes. An analysis published by DrugResearcher of drugs entering clinical trials in 2007 showed that more than twice as many small molecules as biologics made it to first time in man. Although biologics are likely to make up an increasing proportion of new products, there will still be areas where small molecules can achieve better results. Biologics work primarily on disease targets outside the cell, whereas small molecules can also work inside cells. In any therapeutic area, ignoring the intracellular targets may prove costly.
Related posts:
- Biologics and Generics Tipped to Dominate in 2014 Evaluate Pharma predict that the six best selling drugs in 2014 will all be biologics. Despite some recent clinical set-backs,...
- Encouraging News for Rheumatoid Arthritis Sufferers Rheumatoid Arthritis (RA) is a painful, chronic, progressive and disabling auto-immune disease. Newly released data has shown that a novel...
- Promise on the Horizon for Huntington’s Results from a phase II trial of the experimental drug Dimebon (latrepirdine) in people with Huntington’s disease have provided...
- Clinical Applications of siRNA Quark Pharmaceuticals has recently announced that its partner Pfizer has begun a phase II clinical trial of a chemically modified...
- It May be New – But is It Better? This is not a question that the FDA normally asks before approving a new drug, but researchers at Stanford University...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Monday, July 21st, 2008 at 8:09 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)